NCT02711553 2025-08-03A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract CancerEli Lilly and CompanyPhase 2 Active not recruiting309 enrolled 22 charts
NCT02443324 2024-07-31A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract CancerEli Lilly and CompanyPhase 1 Completed175 enrolled 23 charts